Document Detail

Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in type 2 (non-insulin dependent) diabetes mellitus.
MedLine Citation:
PMID:  2647605     Owner:  NLM     Status:  MEDLINE    
The effects of an intravenous infusion of porcine GIP on beta-cell secretion in patients with untreated type 2 diabetes mellitus have been studied. The subjects were studied on two separate days. After a 10 h overnight fast and a further 120 min basal period they were given an intravenous infusion of porcine GIP (2 or control solution in random order from 120-140 min. Frequent plasma glucose, insulin, C-peptide and GIP measurements were made throughout and the study was continued until 200 min. Plasma glucose levels were similar throughout both tests. During the GIP infusion there was an early significant rise in insulin concentration from 0.058 +/- 0.006 nmol/l to 0.106 +/- 0.007 nmol/l (P less than 0.01) within 6 min of commencing the GIP infusion and insulin levels reached a peak of 0.131 +/- 0.011 nmol/l at 10 min (P less than 0.01). Insulin levels remained significantly elevated during the rest of the GIP infusion (P less than 0.01-0.001) and returned to basal values 20 min post infusion. No change in basal insulin values was seen during the control infusion. C-peptide levels were similarly raised during the GIP infusion and the increase was significant just 4 min after commencing the GIP infusion (P less than 0.05). GIP levels increased from 16 +/- 3 pmol/l prior to the infusion to a peak of 286 +/- 24 pmol/l 20 min later. At 4 min when a significant beta-cell response was observed GIP levels were well within the physiological range.(ABSTRACT TRUNCATED AT 250 WORDS)
I R Jones; D R Owens; S Luzio; T M Hayes
Related Documents :
19947815 - Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-li...
12145765 - Glycemic, hormone, and appetite responses to monosaccharide ingestion in patients with ...
15331525 - Therapeutic strategies based on glucagon-like peptide 1.
9525985 - Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
6627255 - Structure of a water-insoluble d-glucan isolated from a streptococcal organism.
14644405 - Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients w...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme     Volume:  21     ISSN:  0018-5043     ISO Abbreviation:  Horm. Metab. Res.     Publication Date:  1989 Jan 
Date Detail:
Created Date:  1989-05-05     Completed Date:  1989-05-05     Revised Date:  2009-02-19    
Medline Journal Info:
Nlm Unique ID:  0177722     Medline TA:  Horm Metab Res     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  23-6     Citation Subset:  IM    
Department of Medicine, University of Wales, College of Medicine, Heath Park, Cardiff, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Glucose / analysis
C-Peptide / analysis
Diabetes Mellitus, Type 2 / metabolism*
Gastric Inhibitory Polypeptide / pharmacology*
Insulin / blood*
Middle Aged
Reg. No./Substance:
0/Blood Glucose; 0/C-Peptide; 11061-68-0/Insulin; 59392-49-3/Gastric Inhibitory Polypeptide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Reduction of postoperative swelling. Objective measurement of swelling of the upper ankle joint in t...
Next Document:  Effect of different insulin administration modalities on vitamin D metabolism of insulin-dependent d...